Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2012 Apr;54(7):979-83. doi: 10.1093/cid/cir882. Epub 2012 Feb 4.

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.

Author information

  • 1Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA. junk7900@verizon.net

Abstract

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

PMID:
22173234
[PubMed - indexed for MEDLINE]
PMCID:
PMC3404695
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk